Article Sidebar
Views pdf: 134
SURVEY OF FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH HOSPITAL-ACQUIRED PNEUMONIA CAUSED BY ACINETOBACTER BAUMANNII AT THE RESPIRATORY DEPARTMENT, CHO RAY HOSPITAL, 2024–2025
Main Article Content
Abstract
Background: Hospital-acquired pneumonia (HAP) caused by multidrug-resistant Acinetobacter baumannii remains a major contributor to increased mortality and prolonged hospital stays in critically ill patients. Identifying factors associated with mortality may help clinicians optimize treatment and improve early prognostication. Objective: To identify factors associated with mortality in patients with HAP caused by A. baumannii treated at the Respiratory Department of Cho Ray Hospital. Subjects and Methods: This was a prospective, cross-sectional descriptive study involving 76 patients diagnosed with HAP and confirmed A. baumannii infection (isolated from respiratory secretions), treated from October 2024 to April 2025. Data collected included clinical characteristics, laboratory findings, antibiotic susceptibility, and patient outcomes. Results: The mortality rate was 46.1%. Pulse rate at admission was significantly different between survivors and non-survivors. Additionally, lymphopenia, thrombocytopenia, and reduced estimated glomerular filtration rate (eGFR) were more pronounced among non-survivors. All A. baumannii isolates were resistant to carbapenems (100%) and classified as multidrug-resistant (100%). High resistance rates were observed for cotrimoxazole (82.9%) and gentamicin (97.4%), while 98.6% remained susceptible to colistin (MIC ≤ 4). Following susceptibility testing, colistin usage increased to 67.1%. Multivariate logistic regression analysis identified thrombocytopenia as significantly associated with mortality (p = 0.003). Conclusion: Hematological and renal function markers may aid in early identification of patients at higher risk of mortality from multidrug-resistant A. baumannii pneumonia
Article Details
Keywords
Pneumonia, hospital-acquired pneumonia, A. baumannii.
References
2. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature Reviews Microbiology. 2007;5(12):939-51.
3. Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med. 2005;31(5):649-55.
4. Dương Bửu Lộc, Hoàng Văn Quang, Hà TTB. Các yếu tố tiên lượng tử vong viêm phổi thở máy do Acinetobacter baumannii ở người cao tuổi. Y Học TP Hồ Chí Minh 2018;22(1):258.
5. Nguyễn Phước An, Phạm Kim Oanh. Khảo sát đặc điểm lâm sàng của bệnh nhân viêm phổi do acinetobacter baumannii điều trị tại bệnh viện bệnh nhiệt đới từ 01/2015 đến 12/2017. Y Học TP Hồ Chí Minh. 2019;23(1):69.
6. Hamilton F, Arnold D, Payne R. Association of prior lymphopenia with mortality in pneumonia: a cohort study in UK primary care. Br J Gen Pract. 2021;71(703):e148-e56.
7. Wang J, Niu H, Wang R, Cai Y. Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis. Int J Antimicrob Agents. 2019;53(4):383-400.
8. Itani R, Khojah HMJ, Karout S, Rahme D, Hammoud L, Awad R, et al. Acinetobacter baumannii: assessing susceptibility patterns, management practices, and mortality predictors in a tertiary teaching hospital in Lebanon. Antimicrob Resist Infect Control. 2023;12(1):136.